David Tougeron

56PUBLICATIONS
221CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (56)

|Aug 17, 2026
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.

|Jul 24, 2026
Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy.

|Jul 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

|Apr 22, 2026
Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.

|Apr 14, 2026
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP.

Christelle de la Fouchardière, Aziz Zaanan, Aymeric de Montfort

|Mar 23, 2026
The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.

Michael Cecchini, Sae-Won Han, Soohyeon Lee

Pageof 10

Frequent Collaborators

12 joint publications

Julien Taieb

11 joint publications

Thomas Aparicio

10 joint publications

Samuel Le Sourd

8 joint publications

Christelle de la Fouchardière